Allink Biotherapeutics Funding: $89M Raised, Series A (2025)
Allink Biotherapeutics is based in Shanghai, China. It has raised $89M in total funding. Latest round: Series A.
Allink Biotherapeutics funding overview
Allink Biotherapeutics is based in Shanghai, China. Allink Biotherapeutics has raised $89M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in December 2025. The round record for Allink Biotherapeutics runs through 2025; nothing later has been disclosed. Investors on record include Lanchi Ventures, Yuanbio Venture Capital, Legend Capital, C&D Emerging Industry Equity Investment, Gaorong Ventures, Med-Fine Capital and 4 others. 10 distinct backers are named across the disclosed rounds.
Frequently asked about Allink Biotherapeutics funding
How much has Allink Biotherapeutics raised?
Allink Biotherapeutics has raised $89M in total disclosed funding across the rounds on record.
Who has invested in Allink Biotherapeutics?
Lanchi Ventures, Yuanbio Venture Capital, Legend Capital, C&D Emerging Industry Equity Investment, Gaorong Ventures, Med-Fine Capital are named among the investors backing Allink Biotherapeutics.
What was the latest Allink Biotherapeutics funding round?
The most recent disclosed round is a Series A, announced in December 2025.
Where is Allink Biotherapeutics based?
Allink Biotherapeutics is based in Shanghai, China.
When did Allink Biotherapeutics last raise?
The last disclosed Allink Biotherapeutics round closed in December 2025 at Series A.
Round data for Allink Biotherapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Shanghai and backer lists below.
